Uncategorized
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.
The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.